Event
XCath $24M Series B (Crescent Enterprises 2022 report)
Key points
- XCath raised additional funding, bringing total capital raised to $24M; Crescent Enterprises cited the round in its 2022 sustainability report.
- The financing supported advancement of XCath's neuro-endovascular robotic platforms toward regulatory clearances and commercialization.
- The round is understood to correspond to XCath's earlier Series B.
Company context
Develops neuro-endovascular surgical robotics and steerable guidewire systems for minimally invasive treatment of cerebrovascular conditions including stroke and brain aneurysms. The company's platform is designed to improve precision and consistency in complex vascular navigation and expand access to neurovascular intervention.
Context
- Company
- XCath
- Segment
- Surgical
- Event type
- Funding
- Geography
- Houston · United States